HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

interferon beta-1b (Betaseron)

Subscribe to New Research on interferon beta-1b

an orphan drug; recombinant human fibroblast interferon in which cysteine is replaced by serine at position 17; currently in Phase II evaluations for diffuse mesothelioma glioma, renal cell carcinoma & hairy cell leukemia; also used in patients with multiple sclerosis

Also Known As:

Betaseron; Beta-Seron; Betaferon; IFN-beta ser; Ser(17) IFN-beta; beta-IFN-1b; interferon beta, Ser(17)-; interferon beta, serine(17)-; interferon beta-1b (recombinant); interferon beta-1b, (2S-(2R*,5R*))-isomer; serine(17) interferon beta; Interferon beta1, 17-L-serine-, (2S-(2R*,5R*))-

Networked: 322 relevant articles (26 outcomes, 91 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kappos, Ludwig: 13 articles (12/2015 - 08/2007)
2.	Sandbrink, Rupert: 12 articles (12/2015 - 08/2007)
3.	Hartung, Hans-Peter: 11 articles (12/2015 - 08/2007)
4.	Kappos, L: 11 articles (11/2014 - 11/2000)
5.	Pohl, Christoph: 10 articles (12/2015 - 08/2007)
6.	Freedman, Mark S: 7 articles (11/2015 - 08/2007)
7.	Montalbán, Xavier: 7 articles (11/2015 - 02/2005)
8.	Beckmann, K: 7 articles (01/2014 - 11/2000)
9.	Pozzilli, C: 7 articles (03/2005 - 11/2000)
10.	O'Connor, Paul: 6 articles (12/2015 - 07/2002)

Related Diseases

1.	Multiple Sclerosis 05/01/2010 - "Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group." 11/01/2014 - "Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome." 08/13/2008 - "Treatment with interferon beta-1b (IFNB-1b) is clinically effective in multiple sclerosis patients. " 11/01/2015 - "All studies that compared the efficacy of the different formulations of IFN-β in patients with relapsing forms of multiple sclerosis including IFN-β-1a Avonex™, IFN-β-1a Rebif™, IFN-β-1b Betaferon/Betaseron™ and IFN-β-1b Extavia™ were included. " 01/01/2011 - "Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials."
2.	Relapsing-Remitting Multiple Sclerosis 07/01/1998 - "Interferon beta-1b (IFNbeta-1b) is effective in reducing the frequency of exacerbations in patients with relapsing-remitting multiple sclerosis (RRMS). " 04/01/1993 - "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. " 04/01/1993 - "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. " 07/01/2013 - "To investigate the relationship between the efficacy of interferon beta-1b (INF-β-1b) on relapsing-remitting multiple sclerosis (RRMS) and the Th17 cells in peripheral blood. " 09/01/2008 - "We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. "
3.	Chronic Progressive Multiple Sclerosis 10/01/2009 - "Our aim is to investigate the safety and efficacy of interferon beta-1b in primary progressive multiple sclerosis. " 11/23/2004 - "A European (EU) and a North American (NA) placebo-controlled study with interferon beta-1b (IFNB-1b) in secondary progressive multiple sclerosis (SPMS) showed divergent results with regard to their primary outcome of sustained Expanded Disability Status Scale (EDSS) progression, while effects were similar on relapse and MRI-related endpoints. " 06/01/2004 - "This short monograph describes a trial of interferon beta-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon beta-1b 8 MIU given subcutaneously every other day for two years. " 09/15/2001 - "With interferon beta-1b (IFN beta-1b), an effective therapeutic option for both relapsing-remitting and secondary progressive multiple sclerosis (RRMS and SPMS, respectively) was on trial. " 11/01/2000 - "European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis."
4.	Fatigue 02/01/1996 - "Thus, if future clinical trials are to provide useful information on the value of interferon beta-1b in progressive MS, the side effects of fatigue and depression will need to be ameliorated to limit the drop-out rate from such trials." 12/01/1992 - "Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-alpha 2b and 17% of patients receiving IFN-beta ser. " 10/01/2010 - "Improvements in fatigue levels were reported for patients receiving subcutaneous interferon beta-1a versus patients in the intramuscular interferon beta-1a group (p = .04) and in the interferon beta-1b group (p = .09). " 06/01/2007 - "A 31-year-old patient with multiple sclerosis (MS), treated with interferon beta-1b (IFNB-1b) for two years, presented with fatigue and dizziness. " 02/01/1996 - "To determine which patients are prone to side effects from interferon beta-1b and which side effects are most troublesome, we studied 72 patients with clinically definite MS who were started on interferon beta-1b after its release and found that the side effects significantly associated with treatment included skin reactions, flu-like symptoms, fatigue, leukopenia, new or worsened depression, and new or worsened headache. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/01/2002 - "This multicenter, controlled Phase III trial failed to confirm the efficacy of Betaseron in patients receiving definitive radiotherapy for locally advanced, nonmetastatic non-small-cell lung cancer. " 10/20/1993 - "Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer."

Related Drugs and Biologics

1.	interferon beta-1b (Betaseron)
2.	copolymer 1 (glatiramer acetate)
3.	Neutralizing Antibodies
4.	interferon beta 1a
5.	Interferon-beta
6.	Steroids
7.	Azathioprine (Imuran)
8.	Interleukin-6 (Interleukin 6)
9.	Messenger RNA (mRNA)
10.	Interleukin-1 (Interleukin 1)

Related Therapies and Procedures

1.	Radiotherapy
2.	Injections
3.	Subcutaneous Injections
4.	Immunomodulation
5.	Off-Label Use